BioNJ Announces the Diamond Circle!
BioNJ is proud to announce the formation of the Diamond Circle. Composed of our Leadership Members and Diamond Members, the Diamond Circle will provide a venue for direct interaction with the BioNJ Board of Trustees on issues affecting the industry, including educational forums that will coincide with regularly scheduled Board Meetings.
The Diamond Circle is just forming. For more information, please contact Kathleen Otto at BioNJ Headquarters by phone at 609-890-3185 or by email.
BioNJ welcomes Merrill DataSite as a new Leadership Member for 2012.
BioNJ is proud to welcome Merrill DataSite as our first Leadership Member. BioNJ created this new Membership level to recognize those companies that are interested in establishing a unique leadership position with BioNJ and the biotechnology community.
The benefits include the opportunities available to the Diamond Circle group along with greatly enhanced visibility and intimate involvement with BioNJ events.
BioNJ welcomes Ipsen Biopharmaceuticals and Polymer Therapeutics, Inc., as new Core Members for 2012.
Ipsen is a global biopharmaceutical group. The group’s specialty care franchise represents more than 60 percent of sales. Ipsen’s development is based on an original model geared towards innovation: commitment to a dynamic investment policy in Research and Development, with a focus on biotechnology (peptides, proteins, steroids, and sustained-release formulations); specialization in four disease areas with high added value (oncology, endocrinology, neurology, hematology), and an historic presence in primary care; an active partnership policy with outstanding research centers and international pharmaceutical companies. Through its long-term development plans, the group aims to transform its knowledge of life sciences into innovative medicines for both physicians and patients.
Polymer Therapeutics, Inc.
Polymer Therapeutics, Inc. (PRx) has developed a novel class of biocompatible polymer drugs (BPD) having broad applications in the wound healing and medical device markets. PRx’s technology incorporates common drug compounds, such as the NSAIDs salicylic acid (SA) and Diflunisal (DF), directly into the chemical structure of the polymer chain itself to produce the BPDs PolySA and PolyDF. These formulations allow the controlled delivery of BPDs with strong anti-inflammatory, analgesic, and antiseptic properties directly at the injury site to promote healing. A key feature of this novel chemistry formulation is that the active compound is synthesized into a polymeric structure and thus becomes an integral part of the polymer backbone.
BioNJ welcomes Chemical and Pharmaceutical Solutions and Managed Market Solutions, LLC (MMS) as new Associate Members for 2012.
Chemical and Pharmaceutical Solutions
Chemical and Pharmaceutical Solutions was founded in 2002. Our primary focus is servicing the emerging pharmaceutical market and assisting those companies in developing and commercializing their APIs. We look at both the technical and regulatory aspects of taking a product from early development through commercial launch. Working with outside partners, we look at economic drivers of your process and the technical challenges around scale-up, including improved purification methods as well as continuous flow chemistry. We also work closely with the venture-capital firms to evaluate the technical and regulatory aspects of potential licensed products.
Managed Market Solutions, LLC
Managed Market Solutions, LLC (MMS) is a software-development company specializing in innovative and custom online marketing systems for its Fortune 500 clients. Our most popular product is Pull-Through Express (PTE), a secure web application designed to streamline the process of ordering sales and marketing resources while tracking their return on investment (ROI). All co-promotes, direct mail, patient education, sales aids, and more are catalogued and controlled in one place. PTE helps coordinate the review and approval of orders across various departments and/or suppliers. Visit our website for a demo!
BioNJ welcomes UBIFRANCE as a new Institutional Member for 2012.
UBIFRANCE, the French agency for international business development, comes under the aegis of France’s Ministry for the Economy, Finance & Industry. With 65 Trade Commissions in 46 countries, UBIFRANCE accompanies French-based innovative companies and high-technology clusters in their international expansion.
- Technology partnering aimed at innovative businesses: UBIFRANCE accompanies innovative businesses to facilitate the joint development of processes, products, and services, in collaboration with companies and R&D facilities based outside of France.
- Innovative clusters’ partnering initiative: UBIFRANCE promotes collaborative projects on behalf of France’s high-tech clusters in order to foster technological cooperation within the innovation ecosystem worldwide.
Each year, the U.S.-based UBIFRANCE HEALTH TEAM works with more than 800 U.S. and 300 cutting-edge French biotech-pharma-medtech companies, including Big Pharma (such as Sanofi, Sanofi-Pasteur, Ipsen, Takeda, GSK, Merck, Abbott, Amgen, Pfizer, etc.) and small and medium-size companies.
Our main recurring events are the French Biotech-Pharma-Medtech Tours, which provide U.S. and French industry professionals with essential contacts and collaborative opportunities (licensing, R&D collaborations, commercial partnerships, etc.). Our goal is to accelerate the development of French companies in the United States by providing advice, access to market information, and business leads to our clients. These partnering events are free of charge for U.S.-based companies, thus providing French companies attending a huge number of opportunities with U.S. companies.
BioNJ thanks Campbell Alliance and Johnson & Johnson for renewing as Diamond Members for 2012.
Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm’s clients include most of the world’s top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit their website.
Johnson & Johnson
The world’s most diversified healthcare company, Johnson & Johnson embraces research and science and works to bring innovative ideas, products, and services to advance the health and well-being of people.
BioNJ thanks Buchanan Ingersoll & Rooney for renewing as a Platinum Member for 2012.
Buchanan Ingersoll & Rooney PC
Buchanan Ingersoll & Rooney PC has more than 450 attorneys and government-relations professionals. The firm’s bicoastal reach provides clients with nationwide access to all of our professionals and their respective areas of experience.
Our attorneys have deep experience in the life sciences industries, in areas such as pharmaceuticals, biotechnology, medical devices, medical foods, and dietary supplements. Other industries that we serve include financial services, energy, entertainment and media, real estate, national security, natural resources, and technology. With regard to the biotechnology industry, our lawyers and professionals are particularly focused on helping clients with U.S. Food and Drug Administration (FDA) and regulatory strategy; Research and Development, lawful marketing and sale of FDA-regulated products, capital formation and corporate finance, intellectual property and patent prosecution; licensing, collaboration, and strategic alliances; government relations; and medical coverage and reimbursement.
We are dedicated to building a deep understanding of our clients, their businesses, and their industries. The proof of our commitment to client service is in what is said about us. Buchanan was recently named on the “Client Service A-Team” for the eighth year in a row in an independent survey conducted by national market research and management consulting firm BTI. The survey consisted of corporate counsel at large and Fortune 1,000 companies.
BioNJ thanks our Core Members who have renewed their memberships for 2012.
Chromocell is a drug-discovery company focused on the identification and development of novel therapeutics against the most complex and challenging drug targets. The company focuses on high-value drug targets and works mainly in pain relief, anxiety treatment, and respiratory disorders.
Ezose Sciences, Inc.
Ezose Sciences, Inc., is pioneering a novel high-throughput solution that allows for the rapid and efficient analyses of glycans present in human blood and other tissues.
Karykion, Inc., has specialties in three therapeutic areas of pharmaceutical research. The first concerns the development of anti-fungal, antibiotics for the treatment of enveloped virus-related disease. The second area of research deals with the identification and treatment of cholesterol-related disease. The research includes studies with cholesterol absorption inhibiting compounds and examining the impact of these products on benign tumor activity. The third area of experimentation has involved the development of products to facilitate the removal of arthropods from living epidermal tissue. The primary species the company has been addressing are ticks.
Roka Bioscience, Inc.
Roka Bioscience, Inc., is a molecular diagnostics company offering highly accurate, cost-effective, easy-to-use molecular assays for biopharmaceutical production, water and food safety testing. In addition to biopharmaceutical, water and food safety testing, Roka Bioscience is in a position to pursue other industrial applications in the future, including veterinary, environmental bioterrorism, and infection control. Established in 2009, Roka’s mission is to become a global leader in molecular diagnostics for industrial applications. Armed with a portfolio of time-tested diagnostic assays applied through innovative automated delivery platforms, Roka’s technology is positioned to be the gold standard for industrial diagnostics.
TAXIS, a Delaware-based subchapter S corporation with operations in New Jersey, was formed in March 2009 by the two scientific founders – Ed LaVoie, Chair of the Department of Medicinal Chemistry, Rutgers, and Dani Pilch, Associate Professor of Pharmacology, UMDNJ – and the chief executive officer, Gregory G. Mario. TAXIS is focusing its current efforts on developing the azachryseniums (AZCs) as a novel class of bactericidal agents that can effectively treat infections caused by MDR bacterial pathogens.
BioNJ thanks our Associate Members who have renewed their memberships for 2012.
Acurian is a leading full-service provider of clinical recruitment solutions for the life sciences industry.
Cushman & Wakefield Global Life Sciences Group
Cushman & Wakefield’s Global Life Sciences Practice Group represents the integration of the firm’s elite life sciences specialists, providing Real Estate Strategy, Project & Asset Management, Tax Incentive Negotiations, Lease Administration, Supply-Chain Logistics Consulting, and Transaction Execution to the Pharmaceutical, Biopharmaceutical, Biotechnology, and Medical Device Sectors on a global level. Our professionals have decades of experience covering all asset classes, including but not limited to R&D, manufacturing, distribution, and office. The practice helps clients to leverage the global markets and effectively maneuver through a fluid landscape in order to improve margins, maximize productivity, and remain competitive in every sector.
Jeiven Pharmaceutical Consulting, Inc.
Jeiven Pharmaceutical Consulting, Inc. (JPC), a New Jersey-based company, has been providing quality guidance to pharmaceutical, biotech, device, and nutraceutical companies for over 20 years, for both clinical and commercial products. Our consulting services comprise, but are not limited to, consulting, training, project management, and staffing services in the areas of GMP, GLP, GCP, and DEA compliance, stability, comparator drug sourcing, Quality Assurance, Quality Control, SOPs, and all regulatory submissions.
Temptime is the world leader in time-temperature indicators that signal if a medical product has been exposed to potentially damaging temperatures. Temptime indicators are cost effective and manufactured under a quality system consistent with the FDA’s Quality System Regulations (QSR) 21 CFR 820. Leading pharmaceutical and medical device companies use Temptime products to protect patients and enhance quality systems.
BioNJ thanks Rutgers Business School for renewing as an Institutional Member for 2012.
Rutgers Business School
Rutgers Business School-Newark and New Brunswick is an integral part of one of the nation’s oldest, largest, and most distinguished institutions of higher learning: Rutgers, The State University of New Jersey – founded in 1766. Rutgers Business School has been accredited since 1941 by AACSB International – the Association to Advance Collegiate Schools of Business – a distinction that represents the hallmark of excellence in management education.